RET原癌基因与非小细胞肺癌的研究现状  

Research updates of RET proto-oncogene in non-small cell lung cancer

作　　者：唐磊 蔡宗佑 常建华 Tang Lei;Cai Zongyou;Chang Jianhua(Department of Oncology,National Cancer Center,National Clinical Research Center for Cancer/Cancer Hospital&Shenzhen Hospital,Chinese Academy of Medical Sciences,Peking Union Medical College,Shenzhen 518116,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院肿瘤内科,深圳518116

出　　处：《国际肿瘤学杂志》2025年第4期237-241,共5页Journal of International Oncology

基　　金：深圳市医学重点学科建设(SZXK013);中国医学科学院肿瘤医院深圳医院院内科研课题(E010221001)。

摘　　要：RET原癌基因编码的RET蛋白是一种受体酪氨酸激酶,可作为非小细胞肺癌(NSCLC)潜在的治疗靶点。在NSCLC中,RET融合变异发生率为1%~2%,多见于年轻、不吸烟患者。传统化疗、免疫治疗和多靶点激酶抑制剂在RET融合NSCLC患者中的疗效有限,但选择性RET抑制剂,如塞普替尼和普拉替尼,显著改善了此类患者的预后。选择性RET抑制剂耐药后的治疗策略是未来的研究方向。The RET protein encoded by RET proto-oncogene is a receptor tyrosine kinase that serves as a potential therapeutic target in non-small cell lung cancer(NSCLC).In NSCLC,the incidence of RET fusions variants ranges from 1%-2%and is more common in younger,non-smoking patients.Traditional chemotherapy,immunotherapy,and multitarget kinase inhibitors have shown limited efficacy in treating RET fusion-positive NSCLC patients.However,selective RET inhibitors,such as selpercatinib and pralsetinib,have significantly improved the prognosis of those patients.The treatment strategy following resistance to selective RET inhibitors is a future research direction.

关 键 词：原癌基因蛋白质c-ret 癌 非小细胞肺 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]